{"id":"sham-to-ranibizumab","safety":{"commonSideEffects":[{"rate":"null","effect":"Intraocular inflammation"},{"rate":"null","effect":"Endophthalmitis"},{"rate":"null","effect":"Retinal detachment"}]},"_chembl":{"chemblId":"CHEMBL1201825","moleculeType":"Antibody"},"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"VEGF-A is a protein that promotes the formation of new blood vessels. By inhibiting VEGF-A, ranibizumab reduces the growth of new blood vessels in the eye, which can help slow vision loss in conditions like age-related macular degeneration.","oneSentence":"Ranibizumab is a monoclonal antibody that inhibits vascular endothelial growth factor A (VEGF-A), preventing angiogenesis.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:34:12.022Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Treatment of neovascular (wet) age-related macular degeneration"},{"name":"Treatment of macular edema following retinal vein occlusion"},{"name":"Treatment of diabetic macular edema"}]},"trialDetails":[{"nctId":"NCT06176352","phase":"PHASE3","title":"A Study to Evaluate the Efficacy and Safety of Faricimab in Patients With Choroidal Neovascularization Secondary to Pathologic Myopia","status":"ACTIVE_NOT_RECRUITING","sponsor":"Hoffmann-La Roche","startDate":"2024-03-06","conditions":"Choroidal Neovascularization Secondary to Pathologic Myopia","enrollment":280},{"nctId":"NCT05151731","phase":"PHASE2","title":"A Study to Investigate Vamikibart (RO7200220) in Diabetic Macular Edema","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2021-12-31","conditions":"Diabetic Macular Edema","enrollment":394},{"nctId":"NCT05151744","phase":"PHASE2","title":"A Study to Investigate Vamikibart (RO7200220) in Combination With Ranibizumab in Diabetic Macular Edema","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2021-12-17","conditions":"Diabetic Macular Edema","enrollment":187},{"nctId":"NCT02243878","phase":"PHASE3","title":"Stereotactic Radiotherapy for Wet AMD (STAR)","status":"COMPLETED","sponsor":"King's College Hospital NHS Trust","startDate":"2014-12","conditions":"Neovascular (Wet) Age-related Macular Degeneration (AMD)","enrollment":411},{"nctId":"NCT04757610","phase":"PHASE3","title":"OPT-302 With Ranibizumab in Neovascular Age-related Macular Degeneration (nAMD)","status":"TERMINATED","sponsor":"Opthea Limited","startDate":"2021-03-12","conditions":"Neovascular Age-related Macular Degeneration","enrollment":986},{"nctId":"NCT02302079","phase":"PHASE2","title":"A Study to Evaluate ASP8232 in Reducing Central Retinal Thickness in Subjects With Diabetic Macular Edema (DME)","status":"COMPLETED","sponsor":"Astellas Pharma Europe B.V.","startDate":"2015-01-12","conditions":"Diabetes Mellitus, Diabetic Macular Edema","enrollment":96},{"nctId":"NCT01940900","phase":"PHASE3","title":"A Phase 3 Safety and Efficacy Study of Fovista® (E10030) Intravitreous Administration in Combination With Lucentis® Compared to Lucentis® Monotherapy","status":"TERMINATED","sponsor":"Ophthotech Corporation","startDate":"2013-08","conditions":"Age-Related Macular Degeneration","enrollment":627},{"nctId":"NCT01944839","phase":"PHASE3","title":"A Phase 3 Safety and Efficacy Study of Fovista® (E10030) Intravitreous Administration in Combination With Lucentis® Compared to Lucentis® Monotherapy","status":"TERMINATED","sponsor":"Ophthotech Corporation","startDate":"2013-08","conditions":"Age-Related Macular Degeneration","enrollment":619},{"nctId":"NCT03784443","phase":"PHASE2, PHASE3","title":"Combined Ranibizumab and Iluvien for Diabetic Macular Oedema","status":"WITHDRAWN","sponsor":"Imperial College London","startDate":"2019-09-01","conditions":"Diabetic Macular Edema, Diabetes","enrollment":""},{"nctId":"NCT03054766","phase":"NA","title":"Combination of Intravitreal Ranibizumab With or Without Macular Laser Photocoagulation for ME Secondary to BRVO","status":"COMPLETED","sponsor":"Beijing Hospital","startDate":"2017-02-14","conditions":"Branch Retinal Vein Occlusion, Ranibizumab, Laser Photocoagulation","enrollment":80},{"nctId":"NCT03211234","phase":"PHASE2","title":"Study Assessing the Efficacy and Safety of Intravitreal Injections of DE-122 in Combination With Lucentis® Compared to Lucentis® Monotherapy in Wet Age-related Macular Degeneration Subjects","status":"COMPLETED","sponsor":"Santen Inc.","startDate":"2017-07-05","conditions":"Age-Related Macular Degeneration","enrollment":76},{"nctId":"NCT03203447","phase":"PHASE3","title":"Suprachoroidal Injection of Triamcinolone Acetonide With IVT Anti-VEGF in Subjects With Macular Edema Following RVO","status":"TERMINATED","sponsor":"Clearside Biomedical, Inc.","startDate":"2018-03-05","conditions":"Macular Edema, Retinal Vein Occlusion","enrollment":325},{"nctId":"NCT03038880","phase":"PHASE2","title":"Study to Evaluate Faricimab (RO6867461; RG7716) for Extended Durability in the Treatment of Neovascular Age Related Macular Degeneration","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2017-01-27","conditions":"Neovascularization, Choroidal, Macular Degeneration, Age-Related","enrollment":76},{"nctId":"NCT02484690","phase":"PHASE2","title":"A Proof-of-Concept Study of Faricimab (RO6867461) in Participants With Choroidal Neovascularization (CNV) Secondary to Age-Related Macular Degeneration (AMD)","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2015-08-11","conditions":"Choroidal Neovascularization","enrollment":273},{"nctId":"NCT02358889","phase":"PHASE2","title":"Study Evaluating Intravitreal hI-con1™ in Patients With Choroidal Neovascularization Secondary to Age-related Macular Degeneration","status":"COMPLETED","sponsor":"Iconic Therapeutics, Inc.","startDate":"2015-02","conditions":"Choroidal Neovascularization, Age-related Macular Degeneration","enrollment":88},{"nctId":"NCT02462486","phase":"PHASE3","title":"Safety and Efficacy of Abicipar Pegol in Participants With Neovascular Age-related Macular Degeneration","status":"COMPLETED","sponsor":"Allergan","startDate":"2015-06-25","conditions":"Macular Degeneration","enrollment":949},{"nctId":"NCT02462928","phase":"PHASE3","title":"A Safety and Efficacy Study of Abicipar Pegol in Participants With Neovascular Age-related Macular Degeneration","status":"COMPLETED","sponsor":"Allergan","startDate":"2015-06-25","conditions":"Macular Degeneration","enrollment":939},{"nctId":"NCT01835067","phase":"PHASE2, PHASE3","title":"Intravitreal tPA and C3F8 for the Treatment of Submacular Haemorrhage as a Complication of Neovascular AMD","status":"COMPLETED","sponsor":"King's College Hospital NHS Trust","startDate":"2014-09","conditions":"Exudative Macular Degeneration, Retinal Hemorrhage","enrollment":55},{"nctId":"NCT04464694","phase":"PHASE4","title":"Pre-vitrectomy Intravitreal Ranibizumab for Patients With Proliferative Diabetic Retinopathy Combined With Diabetic Macular Edema","status":"UNKNOWN","sponsor":"Xinhua Hospital, Shanghai Jiao Tong University School of Medicine","startDate":"2020-09-01","conditions":"Proliferative Diabetic Retinopathy, Diabetic Macular Edema","enrollment":142},{"nctId":"NCT01795209","phase":"PHASE4","title":"Ranibizumab for Macular Edema Secondary to Branch Retinal Vein Occlusion in Patients With Fair Vision","status":"TERMINATED","sponsor":"Seoul National University Bundang Hospital","startDate":"2013-01","conditions":"Branch Retinal Vein Occlusion, Macular Edema","enrollment":19},{"nctId":"NCT03499223","phase":"PHASE2","title":"A Study to Evaluate THR-317 and Ranibizumab Combination Treatment for Diabetic Macular Oedema (DME)","status":"COMPLETED","sponsor":"Oxurion","startDate":"2018-04-20","conditions":"Diabetes Mellitus, Diabetic Retinopathy, Macular Edema","enrollment":70},{"nctId":"NCT00511706","phase":"PHASE2","title":"Safety and Efficacy of a New Treatment as Adjunctive Therapy to Anti-vascular Endothelial Growth Factor (Anti-VEGF) Treatment in Patients With Age-Related Macular Degeneration (AMD)","status":"COMPLETED","sponsor":"Allergan","startDate":"2007-11-01","conditions":"Choroidal Neovascularization, Age-Related Maculopathy","enrollment":243},{"nctId":"NCT02259088","phase":"PHASE3","title":"A 12-month, Randomized, Efficacy and Safety Study of 0.5 mg Ranibizumab vs Laser in Chinese Diabetic Macular Edema (DME) Patients","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2014-11-05","conditions":"Diabetic Macular Edema, Visual Impairment","enrollment":384},{"nctId":"NCT03759860","phase":"PHASE4","title":"Laser (Selective Retina Therapy) and Drug Combined Intervention in Clinically Significant Diabetic Macular Edema","status":"UNKNOWN","sponsor":"CynosureLutronic","startDate":"2018-01-08","conditions":"Diabetic Macular Edema","enrollment":12},{"nctId":"NCT01945866","phase":"PHASE2","title":"Phase II Combination Steroid and Anti-VEGF for Persistent DME","status":"COMPLETED","sponsor":"Jaeb Center for Health Research","startDate":"2014-02","conditions":"Diabetic Macular Edema","enrollment":129},{"nctId":"NCT01213082","phase":"PHASE1, PHASE2","title":"ProspectiveTrial of Proton Beam Combined With Anti-VEGF Therapy for Exudative Age-related Macular Degeneration (AMD)","status":"COMPLETED","sponsor":"University of California, Davis","startDate":"2010-09","conditions":"Exudative Age-related Macular Degeneration","enrollment":34},{"nctId":"NCT03452657","phase":"PHASE3","title":"Multicenter Clinical Study of Anti-VEGF Treatment on High Risk Diabetic Retinopathy (DR)","status":"UNKNOWN","sponsor":"Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine","startDate":"2018-04","conditions":"Diabetic Retinopathy, Ranibizumab","enrollment":118},{"nctId":"NCT02857491","phase":"NA","title":"Intravitreal Injection of Ranibizumab Versus Sham Before Vitrectomy in Patients With Proliferative Diabetic Retinopathy","status":"COMPLETED","sponsor":"Sun Yat-sen University","startDate":"2014-07","conditions":"Proliferative Diabetic Retinopathy","enrollment":90},{"nctId":"NCT00485836","phase":"PHASE3","title":"A Study of the Efficacy and Safety of Ranibizumab Injection in Patients With Macular Edema Secondary to Central Retinal Vein Occlusion (CRUISE)","status":"COMPLETED","sponsor":"Genentech, Inc.","startDate":"2007-07","conditions":"Macular Edema, Retinal Vein Occlusion","enrollment":392},{"nctId":"NCT01976312","phase":"PHASE3","title":"Ranibizumab Intravitreal Injections Versus Sham Control in Patients With Central Retinal Vein Occlusion (CRVO)","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2013-11-12","conditions":"Central Retinal Vein Occlusion","enrollment":252},{"nctId":"NCT00486018","phase":"PHASE3","title":"A Study of the Efficacy and Safety of Ranibizumab Injection in Patients With Macular Edema Secondary to Branch Retinal Vein Occlusion (BRAVO)","status":"COMPLETED","sponsor":"Genentech, Inc.","startDate":"2007-07","conditions":"Macular Edema, Retinal Vein Occlusion","enrollment":397},{"nctId":"NCT01976338","phase":"PHASE3","title":"Ranibizumab Intravitreal Injections Versus Sham Control in Patients With Branch Retinal Vein Occlusion (BRVO)","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2013-11-12","conditions":"Macular Edema Secondary to Branch Retinal Vein Occlusion","enrollment":283},{"nctId":"NCT02181504","phase":"PHASE2","title":"A Study of Abicipar Pegol in Japanese Patients With Neovascular Age-related Macular Degeneration","status":"COMPLETED","sponsor":"Allergan","startDate":"2014-09","conditions":"Macular Degeneration","enrollment":25},{"nctId":"NCT00473330","phase":"PHASE3","title":"A Study of Ranibizumab Injection in Subjects With Clinically Significant Macular Edema (ME) With Center Involvement Secondary to Diabetes Mellitus (RISE)","status":"COMPLETED","sponsor":"Genentech, Inc.","startDate":"2007-06","conditions":"Diabetes Mellitus, Macular Edema","enrollment":377},{"nctId":"NCT00473382","phase":"PHASE3","title":"A Study of Ranibizumab Injection in Subjects With Clinically Significant Macular Edema (ME) With Center Involvement Secondary to Diabetes Mellitus (RIDE)","status":"COMPLETED","sponsor":"Genentech, Inc.","startDate":"2007-06","conditions":"Diabetes Mellitus, Macular Edema","enrollment":382},{"nctId":"NCT02050828","phase":"PHASE2","title":"The TIME-2 Study: A Phase 2 Study of AKB-9778, a Novel Tie-2 Activator, in Patients With Diabetic Macular Edema","status":"COMPLETED","sponsor":"Aerpio Therapeutics","startDate":"2014-01","conditions":"Diabetic Macular Edema (DME)","enrollment":144},{"nctId":"NCT01414153","phase":"PHASE2","title":"Efficacy and Safety Study of iSONEP With & Without Lucentis/Avastin/Eylea to Treat Wet AMD","status":"COMPLETED","sponsor":"Lpath, Inc.","startDate":"2012-08","conditions":"Exudative Age-related Macular Degeneration","enrollment":158},{"nctId":"NCT01994291","phase":"PHASE2","title":"A Phase 2, Multi-Center Study To Compare The Efficacy And Safety Of A Chemokine CCR2/5 Receptor Antagonist With Ranibizumab In Adults With Diabetic Macular Edema","status":"TERMINATED","sponsor":"Pfizer","startDate":"2013-11","conditions":"Macular Edema, Diabetic","enrollment":199},{"nctId":"NCT01396083","phase":"PHASE3","title":"Efficacy and Safety of Ranibizumab Intravitreal Injections Versus Dexamethasone Intravitreal Implant in Patients With Central Retinal Vein Occlusion (CRVO)","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2011-08","conditions":"Visual Impairment, Macular Edema, Central Retinal Vein Occlusion","enrollment":243},{"nctId":"NCT02222207","phase":"PHASE2","title":"Regorafenib Eye Drops: Investigation of Efficacy and Safety in Neovascular Age Related Macular Degeneration","status":"TERMINATED","sponsor":"Bayer","startDate":"2014-10","conditions":"Macular Degeneration","enrollment":52},{"nctId":"NCT00445003","phase":"PHASE3","title":"Laser-Ranibizumab-Triamcinolone for Proliferative Diabetic Retinopathy","status":"COMPLETED","sponsor":"Jaeb Center for Health Research","startDate":"2007-03","conditions":"Proliferative Diabetic Retinopathy, Diabetic Macular Edema","enrollment":333},{"nctId":"NCT01840410","phase":"PHASE3","title":"Assess the Efficacy/Safety of Intravitreal Ranibizumab in Patients With Vision Loss Due to Choroidal Neovascularization.","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2013-09","conditions":"Choroidal Neovascularization (CNV)","enrollment":183},{"nctId":"NCT01846299","phase":"PHASE3","title":"To Assess the Efficacy and Safety of Intravitreal Ranibizumab in People With Vision Loss Due to Macular Edema","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2013-10","conditions":"Macular Edema (ME)","enrollment":181},{"nctId":"NCT02181517","phase":"PHASE2","title":"A Study of Abicipar Pegol in Patients With Neovascular Age-related Macular Degeneration","status":"COMPLETED","sponsor":"Allergan","startDate":"2014-07","conditions":"Macular Degeneration","enrollment":25},{"nctId":"NCT00682539","phase":"PHASE4","title":"Intraocular Anti-VEGF Compared With Intraocular Triamcinolone in Patients With Diabetic Macular Edema","status":"COMPLETED","sponsor":"Medical University of Vienna","startDate":"2007-10","conditions":"Diabetic Macular Edema","enrollment":71},{"nctId":"NCT01827722","phase":"PHASE4","title":"Ozurdex Versus Ranibizumab Versus Combination for Central Retinal Vein Occlusion","status":"UNKNOWN","sponsor":"Valley Retina Institute","startDate":"2013-05","conditions":"Macular Edema, Central Retinal Vein Occlusion","enrollment":45},{"nctId":"NCT02281292","phase":"PHASE1","title":"A Study of the Safety and Tolerability of Intravitreal LKA651 in Patients With Diabetic Macular Edema","status":"WITHDRAWN","sponsor":"Alcon Research","startDate":"2015-12","conditions":"Diabetic Macular Edema","enrollment":""},{"nctId":"NCT02186119","phase":"PHASE2","title":"A Study of Abicipar Pegol in Patients With Diabetic Macular Edema","status":"COMPLETED","sponsor":"Allergan","startDate":"2014-07","conditions":"Macular Edema","enrollment":151},{"nctId":"NCT01016873","phase":"PHASE2","title":"INTREPID - IRay Plus Anti-VEGF Treatment For Patients With Wet AMD","status":"COMPLETED","sponsor":"Oraya Therapeutics, Inc.","startDate":"2009-11","conditions":"AMD, Wet AMD, Age-Related Macular Degeneration","enrollment":230},{"nctId":"NCT01396057","phase":"PHASE3","title":"Efficacy and Safety of Ranibizumab Intravitreal Injections Versus Dexamethasone Intravitreal Implant in Patients With Branch Retinal Vein Occlusion (BRVO)","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2011-07","conditions":"Visual Impairment, Macular Edema, Branch Retinal Vein Occlusion","enrollment":244},{"nctId":"NCT00056836","phase":"PHASE3","title":"A Study to Evaluate rhuFab V2 in Subjects With Minimally Classic or Occult Subfoveal Neovascular Macular Degeneration","status":"COMPLETED","sponsor":"Genentech, Inc.","startDate":"2003-03","conditions":"Macular Degeneration","enrollment":720},{"nctId":"NCT01217944","phase":"PHASE3","title":"Efficacy and Safety of Ranibizumab in Patients With Visual Impairment Due to Choroidal Neovascularization Secondary to Pathologic Myopia","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2010-10","conditions":"Pathological Myopia","enrollment":277},{"nctId":"NCT00931125","phase":"PHASE2","title":"Safety and Efficacy of Intravitreal Ranibizumab as a Preoperative Adjunct Treatment Before Vitrectomy Surgery in Proliferative Diabetic Retinopathy (PDR) Compared to Vitrectomy Alone","status":"UNKNOWN","sponsor":"Attila Vajas","startDate":"2009-03","conditions":"Diabetic Retinopathy","enrollment":70},{"nctId":"NCT00090623","phase":"PHASE3","title":"A Study of rhuFab V2 (Ranibizumab) in Subjects With Subfoveal Choroidal Neovascularization Secondary to Age-Related Macular Degeneration (AMD)","status":"COMPLETED","sponsor":"Genentech, Inc.","startDate":"2004-08","conditions":"Macular Degeneration","enrollment":180},{"nctId":"NCT00687804","phase":"PHASE3","title":"A 12 Month Core Study to Assess the Efficacy and Safety of Ranibizumab (Intravitreal Injections) in Patients With Visual Impairment Due to Diabetic Macular Edema and a 24 Month Open-label Extension Study","status":"COMPLETED","sponsor":"Novartis","startDate":"2008-05","conditions":"Diabetic Macular Edema","enrollment":345},{"nctId":"NCT00509795","phase":"PHASE3","title":"Vascular Endothelial Growth Factor VEGF Trap-Eye:Investigation of Efficacy and Safety in Wet Age-Related Macular Degeneration(AMD)","status":"COMPLETED","sponsor":"Regeneron Pharmaceuticals","startDate":"2007-08","conditions":"Macular Degeneration","enrollment":1217},{"nctId":"NCT00989989","phase":"PHASE3","title":"Efficacy and Safety of Ranibizumab (Intravitreal Injections) in Patients With Visual Impairment Due to Diabetic Macular Edema","status":"COMPLETED","sponsor":"Novartis","startDate":"2009-09","conditions":"Diabetic Macular Edema","enrollment":396},{"nctId":"NCT01122511","phase":"PHASE2","title":"Safety and Efficacy of Dexamethasone as Adjunctive Therapy to Ranibizumab in Subjects With Choroidal Neovascularization and Age-Related Macular Degeneration","status":"TERMINATED","sponsor":"Allergan","startDate":"2010-08","conditions":"Subfoveal Choroidal Neovascularization, Age-Related Maculopathy","enrollment":4},{"nctId":"NCT01131585","phase":"PHASE3","title":"Safety and Efficacy of Ranibizumab in Diabetic Macular Edema","status":"TERMINATED","sponsor":"Novartis Pharmaceuticals","startDate":"2010-06","conditions":"Visual Impairment Due to Diabetic Macular Edema","enrollment":128},{"nctId":"NCT00726973","phase":"NA","title":"Pilot Study Reduced Fluence PDT /Visudyne With Ranibizumab vs Ranibizumab Monotherapy for Exudative Age-related Macular Degeneration (AMD)","status":"WITHDRAWN","sponsor":"Lahey Clinic","startDate":"2006-12","conditions":"Macular Edema","enrollment":""},{"nctId":"NCT00567697","phase":"PHASE3","title":"A Randomized Study Comparing Ranibizumab to Sham in Patients With Macular Edema Secondary to CRVO","status":"COMPLETED","sponsor":"Aleris Helse","startDate":"2007-03","conditions":"Central Retinal Vein Occlusion, Macular Edema","enrollment":32},{"nctId":"NCT01339949","phase":"NA","title":"Study to Evaluate the Safety and Effectiveness of IRay in Wet Age-related Macular Degeneration (AMD) Patients With Recurrent Leakage Secondary to Choroidal Neovascularisation (CNV)","status":"WITHDRAWN","sponsor":"Oraya Therapeutics, Inc.","startDate":"2011-06","conditions":"Wet Age-related Macular Degeneration, Age-related Macular Degeneration, AMD","enrollment":""},{"nctId":"NCT00857259","phase":"PHASE2","title":"The Efficacy of Oral Everolimus in Patients With Neovascular Age-related Macular Degeneration","status":"TERMINATED","sponsor":"Novartis Pharmaceuticals","startDate":"2009-02","conditions":"Choroidal Neo-Vascular Age-onset Macular Degeneration, Age-related Macular Degeneration","enrollment":16},{"nctId":"NCT00433017","phase":"PHASE2, PHASE3","title":"Verteporfin Photodynamic Therapy Administered in Conjunction With Ranibizumab in Patients With Subfoveal Choroidal Neovascularization Secondary to Age-related Macular Degeneration (AMD)","status":"TERMINATED","sponsor":"Novartis","startDate":"2007-05","conditions":"Macular Degeneration, Choroidal Neovascularization","enrollment":255},{"nctId":"NCT00436553","phase":"PHASE3","title":"Efficacy/Safety of Verteporfin Photodynamic Therapy and Ranibizumab Compared With Ranibizumab in Patients With Subfoveal Choroidal Neovascularization","status":"COMPLETED","sponsor":"Novartis","startDate":"2007-02","conditions":"Macular Degeneration, Choroidal Neovascularization","enrollment":321},{"nctId":"NCT00674323","phase":"PHASE4","title":"Efficacy and Safety of Verteporfin Added to Ranibizumab in the Treatment of Symptomatic Macular Polypoidal Choroidal Vasculopathy","status":"COMPLETED","sponsor":"Novartis","startDate":"2008-04","conditions":"Polypoidal Choroidal Vasculopathy","enrollment":61},{"nctId":"NCT00275821","phase":"PHASE3","title":"Efficacy and Safety of Ranibizumab in Patients With Subfoveal Choroidal Neovascularization (CNV) Secondary to Age-related Macular Degeneration (AMD)","status":"COMPLETED","sponsor":"Novartis","startDate":"2005-12","conditions":"Age Related Macular Degeneration","enrollment":353},{"nctId":"NCT00284050","phase":"PHASE2","title":"Safety and Efficacy of Ranibizumab in Diabetic Macular Edema With Center Involvement","status":"COMPLETED","sponsor":"Novartis","startDate":"2005-10","conditions":"Diabetic Macular Edema","enrollment":151}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":201,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Sham to ranibizumab","genericName":"Sham to ranibizumab","companyName":"Novartis","companyId":"novartis","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Ranibizumab is a monoclonal antibody that inhibits vascular endothelial growth factor A (VEGF-A), preventing angiogenesis. Used for Treatment of neovascular (wet) age-related macular degeneration, Treatment of macular edema following retinal vein occlusion, Treatment of diabetic macular edema.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}